Edwards Lifesciences Corporation filings document regulatory disclosures for a Delaware medical technology company with common stock listed on the New York Stock Exchange under EW. Recent Form 8-K reports furnish quarterly and annual operating results, including sales commentary tied to transcatheter aortic valve replacement and transcatheter mitral and tricuspid therapies.
Proxy and material-event filings cover board elections, executive compensation, shareholder voting results, amendments to the Long-Term Stock Incentive Compensation Program, and senior finance leadership changes. These records also identify the company’s registered common stock structure and formal governance matters submitted to stockholders.
Edwards Lifesciences Corp (EW) officer Daniel J. Lippis (CVP, TAVR) exercised 619 employee stock options at $72.68 per share on October 8, 2026, acquiring 619 common shares and selling those shares at $85.65 per share that day. The common-share acquisition and sale were reported pursuant to a Rule 10b5-1 trading plan adopted February 13, 2026. The reported position in the employee stock options after the exercise was 3,095 options.
Edwards Lifesciences Corp (EW) reported that officer Wayne Markowitz, CVP, JAPAC, had common shares withheld to cover tax obligations related to equity vesting. On September 11, 2026, 355 shares were withheld at $86.77 per share, and on September 14, 2026, 568 shares were withheld at $84.37 per share. A footnote states these shares were withheld by the company to satisfy tax withholding obligations incident to vesting under Rule 16b-3(e), rather than representing open-market sales.
Edwards Lifesciences Corp (EW) reported a routine insider equity event for Andrew M. Dahl, SVP and Corporate Controller. On September 13, 2026, 253 shares of common stock were withheld by the company at $84.37 per share to satisfy tax withholding obligations upon vesting, leaving him with 14,615.41 directly held shares.
Edwards Lifesciences Corp (EW) reported that officer Daveen Chopra had 398 shares of common stock withheld on September 11, 2026, to pay tax withholding obligations related to vesting equity awards, treated as a disposition under insider rules. After this withholding, Chopra directly holds 43,926 shares of Edwards Lifesciences common stock. No Rule 10b5-1 trading plan is reported for this transaction.
Edwards Lifesciences Corp (EW) executive Daniel J. Lippis, Corporate Vice President for TAVR, exercised employee stock options covering 619 shares of common stock at an exercise price of $72.68 per share on September 11, 2026, then sold 619 shares at $87.51 per share the same day under a Rule 10b5-1 trading plan. Following the option exercise, he held 3,714 options on Edwards Lifesciences common stock.
Edwards Lifesciences Corp (EW) executive Andrew M. Dahl, SVP, Corporate Controller, reported a sale of 544 shares of Common Stock on 2026-08-31 at $91.055 per share in an open-market or private transaction. After this sale, he directly holds 14,868.41 shares of Edwards Lifesciences common stock. The filing states it reflects changes in beneficial ownership and notes quarterly acquisition of shares under the company’s Employee Stock Purchase Plan. The Rule 10b5-1 trading-plan box is not checked.
Edwards Lifesciences Corp (EW) is the issuer for a notice of proposed sale of securities filed for the account of officer Andrew M. Dahl under Rule 144. The filing covers up to 544 shares of common stock, held at Charles Schwab & Co., Inc., relating to a restricted stock lapse scheduled on 05/08/2026 and designated as Equity Compensation. The common stock is listed on the NYSE. The form indicates an outstanding share count of 576,400,000 common shares, which is a baseline figure for the issuer.
Edwards Lifesciences Corp (EW) reported an insider sale by Annette Bruls, CVP, EMEACLA. On 2026-08-28, she sold 2,644 shares of Common Stock at $89.98 per share in an open market or private transaction. Following this sale, she directly holds 17,984 shares of Edwards Lifesciences common stock.
Edwards Lifesciences Corp (EW) is the issuer for which officer Annette Bruls filed a notice under Rule 144 to permit the sale of common stock. The filing covers up to 2,644 shares of common stock to be sold through Charles Schwab & Co., Inc. on the NYSE, with an aggregate market value of $237,907.00 and total shares outstanding of 576,400,000. The securities to be sold include shares acquired via restricted stock lapses from equity compensation awards.
Edwards Lifesciences Corporation (EW) reported that its Corporate Vice President, Strategy and Corporate Development, Donald E. Bobo, Jr., has notified the company of his decision to retire by mid-year 2027. The board will begin a selection process promptly to identify a successor, with a transition of duties expected during 2027.
The company also states that Mr. Bobo is expected to remain with Edwards as a consultant through the end of 2027, providing continuity during and after the leadership transition.